New drug combo shows promise for Tough-to-Treat leukemia
NCT ID NCT02632708
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-stage study tests whether adding AG-120 or AG-221 to standard chemotherapy is safe for people with a specific type of newly diagnosed acute myeloid leukemia (AML) that has an IDH1 or IDH2 mutation. About 153 adults will receive the study drug alongside standard induction and consolidation therapy, and may continue taking it alone as maintenance until the disease returns, side effects become unacceptable, or they receive a stem cell transplant. The main goal is to track side effects and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02114, United States
-
Erasmus MC
Rotterdam, 3075 EA, Netherlands
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Johns Hopkins University
Baltimore, Maryland, 21231, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina - PPDS
Charleston, South Carolina, 29425-0001, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
UCLA Medical Center
Los Angeles, California, 90024, United States
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.